A sample of our Publications and Presentations:

Publications

1. Reitan J, van Breda A, Corey-Lisle P, et al.  A cross-sectional, observational time and motion study of erythropoiesis-stimulating agent (ESA) use in private practice for anemia due to concomitantly administered myelosuppressive chemotherapy (ACC).  In press, 2011.
2. Adamson RT, Lew I, Beyzarov E, et al.  Clinical and Economic Impact of Intra- and Postoperative Use of Opioids and Analgesic Devices.  2011 to Hosp Pharm. 2011;46(supp):s1-s20.
3. Griffith N, Allen C, Pultz A, Penza S.  The Impact of a Long-Acting Erythropoiesis Stimulating Protein on Patient Throughput in a Hospital-Based Ambulatory Oncology Clinic.  Hosp Pharm.  2008;43:388–395.
4. Beveridge, R., Rifkin, R., Moleski, R., et al. Impact of Long-Acting Growth Factors on Practice Dynamics and Patient Satisfaction. Pharmacotherapy. 2003;23(12 Part 2):101S-109S.
5. Ueno W.  Costs of Outpatient Red Blood Cell Transfusions.  Journal of Supportive Oncology. 2006:4:494-95.
6. Milkovich G, Moleski R, Reitan J, et al.  Comparative Safety of Filgrastim versus Sargramostim in Patients Receiving Myelosuppressive Chemotherapy.  Pharmacotherapy. 2000;20:1432-40.

Poster Presentations

1. Utilization Patterns of Erythropoiesis Stimulating Agents Prescribed for Chemotherapy-Induced Anemia, and the Impact of the Outpatient Regimen on Subsequent Inpatient Use: A Pilot Study.  ASHP Midyear, December 2010.
2. Impact of Long- versus Short Acting Growth Factors on Staff Time Consumption and Utilization: A Multi-Center Study.  ASHP Annual Meeting, June 2006.
3. Impact of a Long-Acting Erythropoietic Growth Factor on Practice Dynamics in an Oncology Clinic.  ASHP Midyear, December 2006.
4. Time Burden of Blood Transfusion.  ASH, December 2005.